Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $11.1152W HIGH $14.77
Volume
65.77 K
Value Traded
2.32 M
Short % Float
8.56%
-2.92%Week
-22.84%1 Month
-30.87%3 Month
-29.28%6 Month
+8.15%5 Year
+8.15%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
276.65 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
99.56 M
Total Shares
33.29 M
Float Shares
12.66 M
Insiders
61.97%
Institutions
17.84%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
MOBI Catalyst Timeline
Dated clinical, regulatory and corporate events for Mobia Medical, Inc.
Past FDA Catalysts and PDUFA Decisions
How MOBI actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Mobia Medical, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every MOBI program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Leavitt Chase C.Officer (SEE REMARKS) | Buy | 2,000 5,000 held | $10.30 | 09/11/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MOBI
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Avidity Partners | 1.7 % | 10.70 M | 798.28 K |
MOBI Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MOBI ranks across every disease it competes in
Competitive Position is a premium feature
See how MOBI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMOBI News
-MOBI
Oct 15, 2026▼ -0.6%today
Mobia Medical to Report Third Quarter 2026 Financial Results on November 5, 2026
Mobia Medical, Inc. will report its third quarter 2026 financial results on November 5, 2026. The company is known for its innovative Vivistim® Paired VNS™ System, which aids stroke recovery. A conference call and webcast will follow the financial report to discuss results and provide updates.
Read more →-MOBI
May 8, 2026Mobia Medical Announces Pricing of Initial Public Offering
Mobia Medical has announced the pricing of its initial public offering, offering 10 million shares at $15.00 each. The IPO is expected to generate gross proceeds of about $150 million. Trading on the Nasdaq Global Select Market is set to begin on May 8, 2026, with the offering closing on May 11, 2026, pending customary conditions.
Read more →About Mobia Medical, Inc.
Headquarters2802 FLINTROCK TRACE, SUITE 226, AUSTIN, TX, 78738
Founded2007
BIOPHARMAWATCH ELITE PLUS
Trade the next MOBI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime